Inhibikase Therapeutics Current Cash

Inhibikase Therapeutics (IKT) currently reports a current cash of $31M as of June 2026. That compares with $78M in the prior-year period — down 59.9% year over year. Use the charts on this page to explore Inhibikase Therapeutics's current cash history and peer comparisons.

Inhibikase Therapeutics's current cash decreased from $78M to $31M — a 59.9% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Inhibikase Therapeutics reported $31M in current cash as of June 2026. That compares with $78M in the prior-year period — down 59.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $31M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Inhibikase Therapeutics, and consider following IKT for alerts when major investors trade the stock.

Inhibikase Therapeutics is classified in the Healthcare sector. On current cash, it currently shows $31M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IKT with unrelated industries.